#USA #Milford #Waters Corporation #BioResolve #Protein A

Waters Corporation Launches BioResolve Protein A Affinity Columns

Waters Corporation has made a significant advancement in bioprocessing with the launch of its new BioResolve™ Protein A Affinity Columns, utilizing MaxPeak™ Premier Technology. This innovative product is designed to transform the landscape in antibody development by providing accelerated measurements of antibody titers and streamlining workflow processes.

Shortcut to Antibody Testing

The introduction of the BioResolve Protein A Affinity Columns allows researchers to obtain antibody titer results up to two days earlier. This time reduction is crucial not just for the selection of clones but also for ongoing bioprocess monitoring. By implementing these new columns, scientists can gain quicker insights, which directly impacts the efficacy of drug development cycles.

Enhanced Sensitivity Features

The new columns boast a remarkable improvement in sensitivity that is reported to be up to seven times greater than leading competitors. This enhanced performance is attributed to high-efficiency, non-porous particles that facilitate accurate quantification of antibody titers even at lower concentrations with minimal sample requirements. This innovation is poised to allow for more reliable and precise measurements that are critical to the development of biopharmaceuticals.

Streamlined Workflows

One of the standout features of the BioResolve columns is their ability to simplify workflows involving multi-attribute assessments. This allows for the simultaneous evaluation of various critical quality attributes, thereby enhancing the efficiency of laboratory procedures. According to Arnaud Delobel, Director of R&D and Innovation at Quality Assistance, the new setup integrates seamlessly into existing LC/MS configurations, making it easier for clients to analyze in-process antibody samples without the need for prior purification steps.

A Commitment to Therapeutic Development

Dr. Udit Batra, CEO of Waters Corporation, emphasized the importance of this launch for expedited patient access to life-saving therapies. By reducing the time required to optimize cell lines necessary for antibody production, this product is set to facilitate faster development timelines for monoclonal antibody therapeutics.

Availability

The BioResolve Protein A Affinity Columns are now available in two formats: 2.1 x 20 mm and 3.9 x 5 mm. Interested customers can place orders through the Waters Corporation website, where detailed application notes and specifications are also provided.

The Legacy of Waters Corporation

Waters Corporation, a leader in analytical instruments and separation technologies, has over 65 years of experience supporting various fields, including life sciences, materials testing, and environmental analysis. The release of the BioResolve columns marks another important step in the company's commitment to innovate and offer solutions that meet the evolving needs of scientists around the globe.

In summary, the launch of the BioResolve Protein A Affinity Columns represents a major leap forward in the field of bioprocessing, providing enhanced agility and efficiency, ultimately leading to faster delivery of new therapies to patients worldwide.

For more details, refer to the official resources available at Waters Corporation.